Skip to main content
Select Search Option
Menu
Weill Cornell Medicine
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
Joint Clinical Trials Office
Joint Clinical Trials Office
Explore this Website
  • Home
  • About
    • News
    • JCTO Contacts
    • Careers
    • Our Clinical Trial Locations
    • Partner with the JCTO
      • JCTO Fees
  • Open Clinical Trials
  • Investigators
  • Patients
    • What is a Clinical Trial?
    • Frequently Asked Questions
    • Clinical Trial Questions to Ask Your Healthcare Team
    • Clinical Trials: Common Terms to Know
    • Understanding Clinical Trials and How They Work
    • Understanding Clinical Trials - In Spanish | En Español
  • Weill Cornell Medicine
  • Care
  • Discover
  • Teach
  • Home
  • About
  • Open Clinical Trials
  • Investigators
  • Patients
  • Home
  • Clinical Trials
Venetoclax In Combination with ASTX727, an All-Oral TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY- MDS/MPN): a Randomized, Phase 2 trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 22, 2025
NRG-GU013: The Phase III `High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 6, 2025
A Multicentre, Prospective, Open-Label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery Or Delivery
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
Use of Blood, Tumor Tissue, and Tumor Infiltrating Lymphocyte Biospecimens for Immune Cell Profiling and Research
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 11, 2025
A Phase 2 Crossover Study Of On-Demand Prep Formulations Comparing Rectal And Oral Tenofovir-Based Prep Evaluating Extended Safety, Acceptability, And Pharmacokinetics/Pharmacodynamics
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy with Lumen-Apposing Metal Stent for Gastric Outlet Obstruction from Malignant Unresectable Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
  • « first
  • ‹ previous
  • …
  • 23
  • 24
  • 25
  • 26
  • 27 (current)
  • 28
  • 29
  • 30
  • 31
  • …
  • next ›
  • last »
Our Location
Joint Clinical Trials Office
Contact Us
  • Twitter
  • Facebook
1300 York Avenue,
Box 305
New York, NY 10065
Phone: (646) 962-8215
Fax: (646) 962-0536
  • About
    • News
    • JCTO Contacts
    • Careers
    • Our Clinical Trial Locations
    • Partner with the JCTO
  • Open Clinical Trials
  • Investigators
  • Patients
    • What is a Clinical Trial?
    • Frequently Asked Questions
    • Clinical Trial Questions to Ask Your Healthcare Team
    • Clinical Trials: Common Terms to Know
    • Understanding Clinical Trials and How They Work
    • Understanding Clinical Trials - In Spanish | En Español
Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and individualized clinical care, making groundbreaking biomedical discoveries, and educating generations of exceptional doctors and scientists.
Weill Cornell Medicine NewYork - Presbyterian
© Weill Cornell Medicine.
  • Privacy & Legal
  • Equal Education & Employment
  • Careers
  • Giving
  • Directory
  • Web Accessibility Assistance